Back to Search Start Over

Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria.

Authors :
Ugwu, Chinedu
Olumade, Testimony
Nwakpakpa, Ebenezer
Onyia, Venatius
Odeh, Elizabeth
Duruiheoma, Rosemary Ogonna
Ojide, Chiedozie K.
Eke, Matthew Afam
Nwafor, Ifeanyi Emmanuel
Chika-Igwenyi, Nneka
Abu, Augustine M.
Azuogu, Benedict
Ajayi, Nnennaya
Ogah, Emeka
Ayodeji, Oluwafemi
Abejegah, Chukwuyem
Adedosu, Nelson
Oyejide, Nicholas
Abah, Sylvester
Omidele, Abiola
Source :
Scientific Reports. 12/25/2022, Vol. 12 Issue 1, p1-9. 9p.
Publication Year :
2022

Abstract

Elucidating the adaptive immune characteristics of natural protection to Lassa fever (LF) is vital in designing and selecting optimal vaccine candidates. With rejuvenated interest in LF and a call for accelerated research on the Lassa virus (LASV) vaccine, there is a need to define the correlates of natural protective immune responses to LF. Here, we describe cellular and antibody immune responses present in survivors of LF (N = 370) and their exposed contacts (N = 170) in a LASV endemic region in Nigeria. Interestingly, our data showed comparable T cell and binding antibody responses from both survivors and their contacts, while neutralizing antibody responses were primarily seen in the LF survivors and not their contacts. Neutralizing antibody responses were found to be cross-reactive against all five lineages of LASV with a strong bias to Lineage II, the prevalent strain in southern Nigeria. We demonstrated that both T cell and antibody responses were not detectable in peripheral blood after a decade in LF survivors. Notably LF survivors maintained high levels of detectable binding antibody response for six months while their contacts did not. Lastly, as potential vaccine targets, we identified the regions of the LASV Glycoprotein (GP) and Nucleoprotein (NP) that induced the broadest peptide-specific T cell responses. Taken together this data informs immunological readouts and potential benchmarks for clinical trials evaluating LASV vaccine candidates. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20452322
Volume :
12
Issue :
1
Database :
Academic Search Index
Journal :
Scientific Reports
Publication Type :
Academic Journal
Accession number :
160956230
Full Text :
https://doi.org/10.1038/s41598-022-26045-w